An interventional study of Minocycline and Celecoxib in Major Depressive Disorder (MDD) and Treatment-resistant Depression (TRD), sponsored by Lahore General Hospital. Completed at 1 site in Pakistan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by Lahore General Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Depressive Disorder, Major with a site in Pakistan — 7 open to participants now, 7 under way, 1 of them phase 3. Depressive Disorder, Major · Pakistan.
Among the 18 studies in Depressive Disorder, Major with a site in Pakistan, this one is the 13th largest by enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2022, is one of 13 with no phase, and was the 18th registered.
3,048 studies on the registry are indexed under Depressive Disorder, Major; 593 are open to participants now.
Browse Depressive Disorder, Major studies →7 of the 18 studies in Depressive Disorder, Major with a site in Pakistan are open now. Recruiting first, the newest first:
Khyber Medical University Peshawar · Sites in Pakistan
Ages 18–60
Dr Sadia yasir · Sites in Pakistan
Ages 18–60
Pakistan Institute of Living and Learning · Sites in Pakistan
Ages 18+ · Women only
Khushal Khan Khattak Univeristy, Karak, Pakistan · Sites in Pakistan
Ages 20–50 · Healthy volunteers
University of Oxford · Sites in Pakistan, Ethiopia, United Kingdom
Ages 18–74
A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →
Of the 414 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 294 (71%) stop at 75 or younger; 55 take children under 18; 99 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 3 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 78 is close to the median of 80 across 2,534 interventional studies indexed under Depressive Disorder, Major.
Median enrollment 80 across the 17 interventional studies, 402 across the 1 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 18 has an industry lead sponsor. The 10 most frequent:
Lahore General Hospital is the lead sponsor of 32 studies on the registry; 4 are open to participants now.
Lahore General Hospital has 1 study filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
2 of the studies in Depressive Disorder, Major with a site in Pakistan that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07703722Phase 3Khyber Medical University PeshawarEffect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Major Depressive Disorder | 2027-10-22 |
| NCT07691749Dr Sadia yasirEffect of Psychobiotics With Standard Antiddepressants in Treatment of Major Depressive Disorder | 2026-12-25 |
Add all 2 to your calendar (.ics) → With an account.
Among the 18 studies in Depressive Disorder, Major with a site in Pakistan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder. Treatment-resistant depression was defined as depression that had not adequately improved despite appropriate previous antidepressant treatment. A total of 78 patients aged 18-65 years were enrolled from the Psychiatry Department of Lahore General Hospital, Lahore, and were randomly assigned to two treatment groups. One group received minocycline 100 mg twice daily with fluoxetine 20-40 mg, while the other group received celecoxib 200 mg twice daily with fluoxetine 20-40 mg. Treatment was continued for 12 weeks.
Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline and during follow-up. The main outcome was the change in HAM-D score from baseline to the end of treatment. Treatment response was defined as a reduction of at least 50% in the HAM-D score, while remission was defined as a final HAM-D score of 7 or lower. The study was designed to test whether adding minocycline or celecoxib to fluoxetine would reduce depressive symptoms in treatment-resistant major depressive disorder and whether the degree of improvement differed between the two adjunctive treatments.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received minocycline 100 mg orally twice daily as adjunctive treatment, along with fluoxetine 20-40 mg orally per day, for 12 weeks.
Drug: Minocycline
Participants received celecoxib 200 mg orally twice daily as adjunctive treatment, along with fluoxetine 20-40 mg orally per day, for 12 weeks.
Drug: Celecoxib
Minocycline 100 mg orally twice daily was administered in addition to fluoxetine 20-40 mg/day for 12 weeks.
Celecoxib 200 mg orally twice daily was administered in addition to fluoxetine 20-40 mg/day for 12 weeks.
Change in Hamilton Depression Rating Scale (HAM-D) Score
The primary outcome was the mean change in Hamilton Depression Rating Scale (HAM-D) score from baseline to the end of treatment. HAM-D was used to assess the severity of depressive symptoms. The change in HAM-D score was calculated by comparing the baseline score with the score obtained after 12 weeks of adjunctive treatment. A greater reduction in HAM-D score indicated greater improvement in depressive symptoms.
Time frame: Baseline and 12 weeks
Treatment Response Based on HAM-D Score
Treatment response was defined as a reduction of 50% or more in the HAM-D score from baseline during the 12-week treatment period. The proportion of participants achieving treatment response was assessed in each treatment group.
Time frame: Baseline to 12 weeks
Ran from May 2022 to primary completion in Jun 2023, 13 months.
Of 651 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's 13 months is below that.
Counting every sponsor, half of 691 studies reached it within 33 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Minocycline
Lahore General Hospital